Enact (NasdaqGS:ACT) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsBose George - Managing DirexctorDaniel Kohl - Head of Investor RelationsDean Mitchell - CFORohit Gupta - CEOConference Call ParticipantsDouglas Harter - Director and Equity AnalystMihir Bhatia - Stock Analyst and Equity ResearchRichard Shane - AnalystOperatorHello, and thank you for standing by. Welcome to Enact fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A ...

Stanley Black & Decker (NYSE:SWK) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsChris Nelson - President and CEOChris Snyder - Executive DirectorMichael Wherley - VP of Investor RelationsNigel Coe - Managing DirectorPat Hallinan - EVP, CFO, and Chief Administrative OfficerRob Wertheimer - Director of ResearchConference Call ParticipantsEric Bosshard - CEO and Consumer AnalystJoe Nolan - Associate AnalystJulian Mitchell - Equity Research AnalystTim Wojs - Senior Research AnalystOper ...

Uber Technologies (NYSE:UBER) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsAlix Anfang - Senior Director of Investor RelationsBalaji Krishnamurthy - Incoming CFODara Khosrowshahi - CEOPrashanth Mahendra-Rajah - CFOConference Call ParticipantsBrian Nowak - AnalystDoug Anmuth - AnalystEric Sheridan - AnalystJohn Colantuoni - AnalystJustin Post - AnalystMark Mahaney - AnalystMichael Morton - AnalystOperatorI'd like to welcome everyone to today's Uber Q4 and full year 2025 earnings co ...

T. Rowe Price Group (NasdaqGS:TROW) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsAlexander Blostein - Managing DirectorBen Budish - DirectorBrennan Hawken - Managing DirectorCraig Siegenthaler - Managing DirectorDan Fannon - Managing DirectorEric Veiel - Head of Global InvestmentsJennifer Dardis - CFOLinsley Carruth - Head of Investor RelationsMichael Cyprys - Managing DirectorPatrick Davitt - PartnerRobert Sharps - CEOConference Call ParticipantsKen Worthington - Senior Equity Re ...

Banco Santander (Brasil) (NYSE:BSBR) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsCamila Toledo - Head of Investor RelationsGustavo Alejo Viviani - CFOMario Roberto Opice Leão - CEOMatheus Guimarães - Equity Research AnalsytYuri Fernandes - Equity Research AnalsytConference Call ParticipantsBrian Flores - Equity Research AnalystCarlos Gomez - Senior Equity Research AnalystDaniel Vaz - Lead Research AnalystEduardo Nishio - Senior Equity AnalystEduardo Rosman - Senior AnalystMarcelo ...

Financial Data and Key Metrics Changes - In 2025, the company added 1.4 million net new digital subscribers, bringing the total to 12.8 million, with a goal of reaching 15 million subscribers [10][18] - Total digital revenues exceeded $2 billion for the first time, with adjusted operating profit (AOP) growing over 20% and margins expanding to 19.5% [10][19] - Digital subscription revenues grew 14% year-over-year, while total subscription revenues increased approximately 9% [22][25] - AOP grew by approximately 21% year-over-year to $550 million, with AOP margin expanding by approximately 190 basis points [19][24] Business Line Data and Key Metrics Changes - Digital advertising revenues increased by 25%, contributing to total advertising revenue growth of 16% [11][22] - Licensing, affiliate, and other revenues grew by 5.5% to $100 million, primarily due to higher licensing revenues [24] - The company reported a digital-only average revenue per user (ARPU) of $9.72, reflecting a positive trend in pricing strategies [21][60] Market Data and Key Metrics Changes - The company experienced strong engagement across its portfolio, which contributed to significant growth in digital advertising [10][11] - The advertising market showed improved demand, allowing the company to secure larger deals with existing marketers and attract new ones [30][77] Company Strategy and Development Direction - The company aims to leverage its world-class journalism and lifestyle products to engage a larger audience, with a focus on video content as a key growth area [12][14] - The strategic priorities for 2026 include enhancing journalism formats, expanding product offerings, and navigating technological changes to increase value for audiences [15][26] - The company plans to continue investing in high-quality journalism and digital product experiences while maintaining operational efficiency [25][32] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in the media landscape, including a polarized environment and competition from powerful platforms, but expressed confidence in the company's strategic positioning [11][12] - The outlook for 2026 includes expectations for continued subscriber growth, revenue growth, AOP growth, margin expansion, and strong free cash flow generation [15][26] Other Important Information - The company returned approximately $275 million to shareholders in 2025, including $165 million in share repurchases and $110 million in dividends [19][20] - The quarterly dividend was increased from $0.18 to $0.23, aligning with the company's capital allocation strategy [20][38] Q&A Session Summary Question: Digital ad growth breakdown - Management noted that digital ad growth was driven by increased supply, improved engagement, and a stronger demand environment [28][30] Question: Cost guidance for Q1 - Management explained that the cost guidance reflects ongoing investments in video and other strategic areas, while maintaining a focus on revenue growth outpacing cost growth [32][33] Question: Capital allocation strategy - The company reiterated its commitment to returning at least 50% of free cash flow to shareholders while prioritizing organic investments in its subscription strategy [37][38] Question: Password sharing approach - Management discussed the Family Plan as a way to encourage engagement and revenue growth, viewing it as a positive strategy rather than a punitive measure [40][41] Question: Video journalism initiative - The company sees video as a significant long-term opportunity and is ramping up production to establish itself as a preferred brand for news consumption [46][48] Question: Single product growth and conversion potential - Management expressed confidence in the ability to convert engaged single product users into more valuable bundle subscriptions, highlighting the interconnectedness of their product offerings [81][82] Question: Contract negotiations with NewsGuild - Management indicated confidence in navigating contract negotiations with unions, emphasizing a history of productive relationships [87]

Champion Homes (NYSE:SKY) Q3 2026 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsDaniel Moore - CFADave McKinstry - EVP and CFOJesse Lederman - CFALaurie Hough - Former EVP and CFOPhilip Ng - Managing Director and senior equity research analystTim Larson - CEOConference Call ParticipantsGreg Palm - Senior Research AnalystMatthew Bouley - Director and Senior Equity Research AnalystMike Dahl - Managing Director and Senior Equity Research AnalystOperatorGood morning, and welcome to the Champio ...

Enact (NasdaqGS:ACT) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Speaker5Hello, and thank you for standing by. Welcome to Enact fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask the question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, p ...

Financial Data and Key Metrics Changes - Novartis achieved high single-digit growth with an 8% increase in sales and a 14% rise in core operating income for the full year 2025, reaching a core margin of 40.1% [4][35] - For Q4, sales declined by 1%, while core operating income increased by 1%, with core EPS rising 2% to $2.03 [5][38] - Free cash flow reached an all-time high of CHF 17.6 billion, growing 8% year-over-year [35][39] Business Line Data and Key Metrics Changes - Kisqali sales grew 57% year-over-year to CHF 4.8 billion, with Q4 growth at 44% [6][7] - Kesimpta saw a 36% increase to $4.4 billion, with a 27% growth in Q4 [10] - Pluvicto achieved $2 billion in global sales, with a 75% increase in the U.S. [12] - Leqvio reached blockbuster status with 57% growth for the year [14] - Scemblix also reached blockbuster status with 87% growth in Q4 [15] Market Data and Key Metrics Changes - Kisqali's U.S. sales growth was 62%, with over 80% NBRX share in Germany for early breast cancer [7][9] - Kesimpta is leading in NBRX share in 9 out of 10 major markets outside the U.S. [10] - Pluvicto secured approvals in Japan and China, contributing to strong growth outside the U.S. [12] - Scemblix has a 41% NBRX share in the U.S. and 72% in the third-line setting across major markets [17] Company Strategy and Development Direction - Novartis aims to grow through the largest patent expiry in its history, focusing on key growth brands and pipeline replacement [6] - The company plans to continue investing in R&D while managing productivity improvements [43][44] - Novartis is committed to maintaining a 5%-6% sales CAGR from 2025 to 2030 [44][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit sales growth in 2026 despite anticipated challenges from generic entries [43][44] - The company expects to return to a core margin of over 40% by 2029 [44] - Management highlighted the importance of pipeline advancements and upcoming pivotal readouts in 2026 [32][50] Other Important Information - Novartis has completed its CHF 15 billion share buyback program and initiated a new CHF 10 billion program [41] - The proposed dividend for 2025 is CHF 3.70 per share, marking a 6% increase [41][42] Q&A Session Questions and Answers Question: Insights on remibrutinib and FDA conversations - Management noted that remibrutinib has an approved label without liver safety discussions, and they plan to advocate for limited liver monitoring based on FDA feedback [53][54] Question: Commercial opportunities for remibrutinib in MS - Management indicated that the commercial opportunity will depend on data-driven results, with a significant market for oral options in MS [60][61] Question: Thoughts on Pelacarsen's event-based study risks - Management expressed confidence in the study's design and powering assumptions, despite lower than expected event rates [62][63] Question: Launch plans for Rhapsido and Ianalumab in an MFN world - Management acknowledged the importance of adjusting launch strategies for significant assets like Rhapsido and Ianalumab in the ex-U.S. market [73]

Banco Santander (Brasil) (NYSE:BSBR) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Speaker3Good morning, everyone. Thank you for joining us for our fourth quarter 2025 earnings video conference call. We are live from our headquarters in São Paulo, and we will divide this event into three parts. First, Mário Leão will address the main highlights of the quarter and the directions for our growth in the coming periods. Next, Gustavo Alejo will provide a detailed analysis of our performance, and finally, w ...